Roche released phase‑3 results showing its BTK inhibitor fenebrutinib achieved non‑inferiority versus Ocrevus (ocrelizumab) in primary progressive multiple sclerosis (PPMS), cutting the risk of disability progression by about 12%. The company presented detailed data at ACTRIMS26 and emphasized the agent’s potential to challenge an established MS therapy. Roche framed the result as validation of BTK inhibition in progressive MS and provided numbers intended to reassure investors and clinicians worried about differentiation from its own legacy therapies. The dataset will inform regulatory and payer discussions as Roche advances fenebrutinib’s clinical positioning.